Seattle-based Umoja Biopharma has raised a $100 million Series C round. With the funding, announced Tuesday, Umoja wants to advance its clinical pipeline. Its lead drug, UB-VV400 is aimed at cancer ...

It’s a kind of control that no one has ever tried before in patients,” Tune’s chief scientific officer said Monday.

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Its lead candidate Tune-401, which aims to repress viral DNA that contributes to infection, has entered into clinical trials in New Zealand and Hong Kong.

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest ...

Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

NEW YORK – MOMA Therapeutics on Wednesday said it added the next-generation PARP1 inhibitor MOMA-989 to its pipeline of drug candidates and anticipates filing an investigational new drug application ...

DANIA BEACH, Fla. (AP) — It was some combination of religion, a grudge involving Knute Rockne and maybe the simple notion that some people just don't like Notre Dame. Back in the 1920s, the Fighting ...